EDP Sciences logo
Authentification abonné
rechercher
Menu
Accueil Tous les numéros Volume 202 / Numéro 4 (2008) J. Soc. Biol., 202 4 (2008) 289-312 Références
Accès gratuit
Numéro
J. Soc. Biol.
Volume 202, Numéro 4, 2008
Os et cartilage - Structure, métabolisme, vieillissement
Page(s) 289 - 312
DOI https://doi.org/10.1051/jbio:2008034
Publié en ligne 19 décembre 2008
  • Afif H., Benderdour M., Mfuna-Endam L., Martel-Pelletier J., Pelletier J.P., Duval N. & Fahmi H., Peroxisome proliferator-activated receptor gamma1 expression is diminished in human osteoarthritic cartilage and is downregulated by interleukin-1beta in articular chondrocytes. Arthritis Res Ther, 2007, 9, 2, R31. [CrossRef] [PubMed] [Google Scholar]
  • Ali A.A., Weinstein R.S., Stewart S.A., Parfitt A.M., Manolagas S.C. & Jilka R.L., Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology, 2005, 146, 3, 1226–1235. [CrossRef] [PubMed] [Google Scholar]
  • Arend W.P., Malyak M., Guthridge C.J. & Gabay C., Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol, 1998, 16, 27–55. [CrossRef] [PubMed] [Google Scholar]
  • Bell-Parikh L.C., Ide T., Lawson J.A., McNamara P., Reilly M. & FitzGerald G.A., Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARgamma. J Clin Invest, 2003, 112, 6, 945–955. [PubMed] [Google Scholar]
  • Bianchi A., Moulin D., Sebillaud S., Koufany M., Galteau M.M., Netter P., Terlain B. & Jouzeau J.Y., Contrasting effects of peroxisome-proliferator-activated receptor (PPAR)gamma agonists on membrane-associated prostaglandin E2 synthase-1 in IL-1beta-stimulated rat chondrocytes: evidence for PPARgamma-independent inhibition by 15-deoxy-Delta12,14prostaglandin J2. Arthritis Res Ther, 2005, 7, 6, R1325–1337. [CrossRef] [PubMed] [Google Scholar]
  • Bishop-Bailey D. & Wray J., Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation. Prostaglandins Other Lipid Mediat, 2003, 71, 1–2, 1–22. [CrossRef] [PubMed] [Google Scholar]
  • Blanco F.J., Guitian R., Moreno J., de Toro F.J. & Galdo F., Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J Rheumatol, 1999, 26, 6, 1366–1373. [PubMed] [Google Scholar]
  • Blanco F.J., Guitian R., Vazquez-Martul E., de Toro F.J. & Galdo F., Osteoarthritis chondrocytes die by apoptosis. A possible pathway for osteoarthritis pathology. Arthritis Rheum, 1998, 41, 2, 284–289. [CrossRef] [PubMed] [Google Scholar]
  • Blanquart C., Mansouri R., Fruchart J.C., Staels B. & Glineur C., Different ways to regulate the PPARalpha stability. Biochem Biophys Res Commun, 2004, 319, 2, 663–670. [CrossRef] [PubMed] [Google Scholar]
  • Blaschke F., Takata Y., Caglayan E., Law R.E. & Hsueh W.A., Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes. Arterioscler Thromb Vasc Biol, 2006, 26, 1, 28–40. [CrossRef] [PubMed] [Google Scholar]
  • Boileau C., Martel-Pelletier J., Fahmi H., Mineau F., Boily M. & Pelletier J.P., The peroxisome proliferator-activated receptor gamma agonist pioglitazone reduces the development of cartilage lesions in an experimental dog model of osteoarthritis: in vivo protective effects mediated through the inhibition of key signaling and catabolic pathways. Arthritis Rheum, 2007, 56, 7, 2288–2298. [CrossRef] [PubMed] [Google Scholar]
  • Bondeson J., Wainwright S., Hughes C. & Caterson B., The regulation of the ADAMTS4 and ADAMTS5 aggrecanases in osteoarthritis: a review. Clin Exp Rheumatol, 2008, 26, 1, 139–145. [PubMed] [Google Scholar]
  • Bordji K., Grillasca J.P., Gouze J.N., Magdalou J., Schohn H., Keller J.M., Bianchi A., Dauca M., Netter P. & Terlain B., Evidence for the presence of peroxisome proliferator-activated receptor (PPAR) alpha and gamma and retinoid Z receptor in cartilage. PPARgamma activation modulates the effects of interleukin-1beta on rat chondrocytes. J Biol Chem, 2000, 275, 16, 12243–12250. [CrossRef] [PubMed] [Google Scholar]
  • Boyault S., Bianchi A., Moulin D., Morin S., François M., Netter P., Terlain B. & Bordji K., 15-Deoxy-delta(12,14)-prostaglandin J(2) inhibits IL-1beta-induced IKK enzymatic activity and IkappaBalpha degradation in rat chondrocytes through a PPARgamma-independent pathway. FEBS Lett, 2004, 572, 1–3, 33–40. [CrossRef] [PubMed] [Google Scholar]
  • Boyault S., Simonin M.A., Bianchi A., Compe E., Liagre B., Mainard D., Becuwe P., Dauca M., Netter P., Terlain B. & Bordji K., 15-Deoxy-delta12,14-PGJ2, but not troglitazone, modulates IL-1beta effects in human chondrocytes by inhibiting NF-kappaB and AP-1 activation pathways. FEBS Lett, 2001, 501, 1, 24–30. [CrossRef] [PubMed] [Google Scholar]
  • Braissant O., Foufelle F., Scotto C., Dauca M. & Wahli W., Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology, 1996, 137, 1, 354–366. [CrossRef] [PubMed] [Google Scholar]
  • Bresnihan B., Alvaro-Gracia J.M., Cobby M., Doherty M., Domljan Z., Emery P., Nuki G., Pavelka K., Rau R., Rozman B., Watt I., Williams B., Aitchison R., McCabe D. & Musikic P., Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum, 1998, 41, 12, 2196–2204. [CrossRef] [PubMed] [Google Scholar]
  • Brewster M., Lewis E.J., Wilson K.L., Greenham A.K. & Bottomley K.M., Ro 32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis. Arthritis Rheum, 1998, 41, 9, 1639–1644. [CrossRef] [PubMed] [Google Scholar]
  • Burgess H.A., Daugherty L.E., Thatcher T.H., Lakatos H.F., Ray D.M., Redonnet M., Phipps R.P. & Sime P.J., PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. Am J Physiol Lung Cell Mol Physiol, 2005, 288, 6, L1146–1153. [CrossRef] [PubMed] [Google Scholar]
  • Calder P.C., n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr, 2006, 83, 6 Suppl, 1505S–1519S. [Google Scholar]
  • Caterson B., Flannery C.R., Hughes C.E. & Little C.B., Mechanisms involved in cartilage proteoglycan catabolism. Matrix Biol, 2000, 19, 4, 333–344. [CrossRef] [PubMed] [Google Scholar]
  • Chan B.Y., Gartland A., Wilson P.J., Buckley K.A., Dillon J.P., Fraser W.D. & Gallagher J.A., PPAR agonists modulate human osteoclast formation and activity in vitro. Bone, 2007, 40, 1, 149–159. [CrossRef] [PubMed] [Google Scholar]
  • Cheng P.T. & Mukherjee R., PPARs as targets for metabolic and cardiovascular diseases. Mini Rev Med Chem, 2005, 5, 8, 741–753. [CrossRef] [PubMed] [Google Scholar]
  • Cheng S., Afif H., Martel-Pelletier J., Pelletier J.P., Li X., Farrajota K., Lavigne M. & Fahmi H., Activation of peroxisome proliferator-activated receptor gamma inhibits interleukin-1beta-induced membrane-associated prostaglandin E2 synthase-1 expression in human synovial fibroblasts by interfering with Egr-1. J Biol Chem, 2004, 279, 21, 22057–22065. [CrossRef] [PubMed] [Google Scholar]
  • Chinetti G., Griglio S., Antonucci M., Torra I.P., Delerive P., Majd Z., Fruchart J.C., Chapman J., Najib J. & Staels B., Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem, 1998, 273, 40, 25573–25580. [CrossRef] [PubMed] [Google Scholar]
  • Chung S.W., Kang B.Y. & Kim T.S., Inhibition of interleukin-4 production in CD4+ T cells by peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands: involvement of physical association between PPAR-gamma and the nuclear factor of activated T cells transcription factor. Mol Pharmacol, 2003, 64, 5, 1169–1179. [CrossRef] [PubMed] [Google Scholar]
  • Clark C.A., Schwarz E.M., Zhang X., Ziran N.M., Drissi H., O'Keefe R.J. & Zuscik M.J., Differential regulation of EP receptor isoforms during chondrogenesis and chondrocyte maturation. Biochem Biophys Res Commun, 2005, 328, 3, 764–776. [CrossRef] [PubMed] [Google Scholar]
  • Close D.R., Matrix metalloproteinase inhibitors in rheumatic diseases. Ann Rheum Dis, 2001, 60 Suppl 3, iii62–67. [Google Scholar]
  • Cunard R., Ricote M., DiCampli D., Archer D.C., Kahn D.A., Glass C.K. & Kelly C.J., Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors. J Immunol, 2002, 168, 6, 2795–2802. [PubMed] [Google Scholar]
  • Curtis C.L., Hughes C.E., Flannery C.R., Little C.B., Harwood J.L. & Caterson B., n-3 fatty acids specifically modulate catabolic factors involved in articular cartilage degradation. J Biol Chem, 2000, 275, 2, 721–724. [CrossRef] [PubMed] [Google Scholar]
  • Cuzzocrea S., Mazzon E., Dugo L., Patel N.S., Serraino I., Di Paola R., Genovese T., Britti D., De Maio M., Caputi A.P. & Thiemermann C., Reduction in the evolution of murine type II collagen-induced arthritis by treatment with rosiglitazone, a ligand of the peroxisome proliferator-activated receptor gamma. Arthritis Rheum, 2003, 48, 12, 3544–3556. [CrossRef] [PubMed] [Google Scholar]
  • Cuzzocrea S., Pisano B., Dugo L., Ianaro A., Maffia P., Patel N.S., Di Paola R., Ialenti A., Genovese T., Chatterjee P.K., Di Rosa M., Caputi A.P. & Thiemermann C., Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation. Eur J Pharmacol, 2004, 483, 1, 79–93. [CrossRef] [PubMed] [Google Scholar]
  • Cuzzocrea S., Wayman N.S., Mazzon E., Dugo L., Di Paola R., Serraino I., Britti D., Chatterjee P.K., Caputi A.P. & Thiemermann C., The cyclopentenone prostaglandin 15-deoxy-Delta(12,14)-prostaglandin J(2) attenuates the development of acute and chronic inflammation. Mol Pharmacol, 2002, 61, 5, 997–1007. [CrossRef] [PubMed] [Google Scholar]
  • Daynes R.A. & Jones D.C., Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol, 2002, 2, 10, 748–759. [CrossRef] [PubMed] [Google Scholar]
  • Delerive P., Fruchart J.C. & Staels B., Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol, 2001, 169, 3, 453–459. [CrossRef] [PubMed] [Google Scholar]
  • Desreumaux P., Dubuquoy L., Nutten S., Peuchmaur M., Englaro W., Schoonjans K., Derijard B., Desvergne B., Wahli W., Chambon P., Leibowitz M.D., Colombel J.F. & Auwerx J., Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J Exp Med, 2001, 193, 7, 827–838. [CrossRef] [PubMed] [Google Scholar]
  • Desvergne B., A I.J., Devchand P.R. & Wahli W., The peroxisome proliferator-activated receptors at the cross-road of diet and hormonal signalling. J Steroid Biochem Mol Biol, 1998, 65, 1–6, 65–74. [CrossRef] [PubMed] [Google Scholar]
  • Devchand P.R., Keller H., Peters J.M., Vazquez M., Gonzalez F.J. & Wahli W., The PPARalpha-leukotriene B4 pathway to inflammation control. Nature, 1996, 384, 6604, 39–43. [CrossRef] [PubMed] [Google Scholar]
  • Dinarello C.A., Biologic basis for interleukin-1 in disease. Blood, 1996, 87, 6, 2095–2147. [PubMed] [Google Scholar]
  • Diradourian C., Girard J. & Pegorier J.P., Phosphorylation of PPARs: from molecular characterization to physiological relevance. Biochimie, 2005, 87, 1, 33–38. [CrossRef] [PubMed] [Google Scholar]
  • Dumond H., Presle N., Pottie P., Pacquelet S., Terlain B., Netter P., Gepstein A., Livne E. & Jouzeau J.Y., Site specific changes in gene expression and cartilage metabolism during early experimental osteoarthritis. Osteoarthritis Cartilage, 2004, 12, 4, 284–295. [CrossRef] [PubMed] [Google Scholar]
  • Fahmi H., Di Battista J.A., Pelletier J.P., Mineau F., Ranger P. & Martel-Pelletier J., Peroxisome proliferator–activated receptor gamma activators inhibit interleukin-1beta-induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes. Arthritis Rheum, 2001, 44, 3, 595–607. [CrossRef] [PubMed] [Google Scholar]
  • Fahmi H., Pelletier J.P., Mineau F. & Martel-Pelletier J., 15d-PGJ(2) is acting as a 'dual agent' on the regulation of COX-2 expression in human osteoarthritic chondrocytes. Osteoarthritis Cartilage, 2002, 10, 11, 845–848. [CrossRef] [PubMed] [Google Scholar]
  • Faour W.H., He Y., He Q.W., de Ladurantaye M., Quintero M., Mancini A. & Di Battista J.A., Prostaglandin E(2) regulates the level and stability of cyclooxygenase-2 mRNA through activation of p38 mitogen-activated protein kinase in interleukin-1 beta-treated human synovial fibroblasts. J Biol Chem, 2001, 276, 34, 31720–31731. [CrossRef] [PubMed] [Google Scholar]
  • Farrajota K., Cheng S., Martel-Pelletier J., Afif H., Pelletier J.P., Li X., Ranger P. & Fahmi H., Inhibition of interleukin-1beta-induced cyclooxygenase 2 expression in human synovial fibroblasts by 15-deoxy-Delta12,14-prostaglandin J2 through a histone deacetylase-independent mechanism. Arthritis Rheum, 2005, 52, 1, 94–104. [CrossRef] [PubMed] [Google Scholar]
  • Farrell A.J., Blake D.R., Palmer R.M. & Moncada S., Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann Rheum Dis, 1992, 51, 11, 1219–1222. [CrossRef] [PubMed] [Google Scholar]
  • Firestein G.S., Boyle D.L., Yu C., Paine M.M., Whisenand T.D., Zvaifler N.J. & Arend W.P., Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum, 1994, 37, 5, 644–652. [CrossRef] [PubMed] [Google Scholar]
  • Fonseca V., Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med, 2003, 115 Suppl 8A, 42S–48S. [Google Scholar]
  • Forman B.M., Chen J. & Evans R.M., The peroxisome proliferator-activated receptors: ligands and activators. Ann N Y Acad Sci, 1996, 804, 266–275. [CrossRef] [PubMed] [Google Scholar]
  • Fourcade S., Savary S., Albet S., Gauthe D., Gondcaille C., Pineau T., Bellenger J., Bentejac M., Holzinger A., Berger J. & Bugaut M., Fibrate induction of the adrenoleukodystrophy-related gene (ABCD2): promoter analysis and role of the peroxisome proliferator-activated receptor PPARalpha. Eur J Biochem, 2001, 268, 12, 3490–3500. [CrossRef] [PubMed] [Google Scholar]
  • François M., Richette P. & Corvol M.T., Peroxisome proliferator-activated receptor gamma and its ligands in controlling interleukin-1beta target gene expression: a confusing story. Drug News Perspect, 2005, 18, 4, 257–261. [CrossRef] [PubMed] [Google Scholar]
  • François M., Richette P., Tsagris L., Fitting C., Lemay C., Benallaoua M., Tahiri K. & Corvol M.T., Activation of the peroxisome proliferator-activated receptor alpha pathway potentiates interleukin-1 receptor antagonist production in cytokine-treated chondrocytes. Arthritis Rheum, 2006, 54, 4, 1233–1245. [CrossRef] [PubMed] [Google Scholar]
  • François M., Richette P., Tsagris L., Raymondjean M., Fulchignoni-Lataud M.C., Forest C., Savouret J.F. & Corvol M.T., Peroxisome proliferator-activated receptor-gamma down-regulates chondrocyte matrix metalloproteinase-1 via a novel composite element. J Biol Chem, 2004, 279, 27, 28411–28418. [CrossRef] [PubMed] [Google Scholar]
  • Fuenzalida K., Quintanilla R., Ramos P., Piderit D., Fuentealba R.A., Martinez G., Inestrosa N.C. & Bronfman M., Peroxisome proliferator-activated receptor gamma up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis. J Biol Chem, 2007, 282, 51, 37006–37015. [Google Scholar]
  • Fujita Y., Yamada Y., Kusama M., Yamauchi T., Kamon J., Kadowaki T. & Iga T., Sex differences in the pharmacokinetics of pioglitazone in rats. Comp Biochem Physiol C Toxicol Pharmacol, 2003, 136, 1, 85–94. [CrossRef] [PubMed] [Google Scholar]
  • Fukushima M., Biological activities and mechanisms of action of PGJ2 and related compounds: an update. Prostaglandins Leukot Essent Fatty Acids, 1992, 47, 1, 1–12. [CrossRef] [PubMed] [Google Scholar]
  • Gervois P., Chopin-Delannoy S., Fadel A., Dubois G., Kosykh V., Fruchart J.C., Najib J., Laudet V. & Staels B., Fibrates increase human REV-ERBalpha expression in liver via a novel peroxisome proliferator-activated receptor response element. Mol Endocrinol, 1999, 13, 3, 400–409. [CrossRef] [PubMed] [Google Scholar]
  • Ghosh A.K., Bhattacharyya S., Lakos G., Chen S.J., Mori Y. & Varga J., Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma. Arthritis Rheum, 2004, 50, 4, 1305–1318. [CrossRef] [PubMed] [Google Scholar]
  • Gilde A.J., van der Lee K.A., Willemsen P.H., Chinetti G., van der Leij F.R., van der Vusse G.J., Staels B. & van Bilsen M., Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res, 2003, 92, 5, 518–524. [CrossRef] [PubMed] [Google Scholar]
  • Gilroy D.W., Colville-Nash P.R., Willis D., Chivers J., Paul-Clark M.J. & Willoughby D.A., Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med, 1999, 5, 6, 698–701. [Google Scholar]
  • Glasson S.S., Askew R., Sheppard B., Carito B., Blanchet T., Ma H.L., Flannery C.R., Peluso D., Kanki K., Yang Z., Majumdar M.K. & Morris E.A., Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature, 2005, 434, 7033, 644–648. [CrossRef] [PubMed] [Google Scholar]
  • Glasson S.S., Askew R., Sheppard B., Carito B.A., Blanchet T., Ma H.L., Flannery C.R., Kanki K., Wang E., Peluso D., Yang Z., Majumdar M.K. & Morris E.A., Characterization of and osteoarthritis susceptibility in ADAMTS-4-knockout mice. Arthritis Rheum, 2004, 50, 8, 2547–2558. [CrossRef] [PubMed] [Google Scholar]
  • Goldring M.B., The role of the chondrocyte in osteoarthritis. Arthritis Rheum, 2000, 43, 9, 1916–1926. [CrossRef] [PubMed] [Google Scholar]
  • Gonzalez-Gay M.A., Gonzalez-Juanatey C., Miranda-Filloy J.A., Garcia-Porrua C., Llorca J. & Martin J., Cardiovascular disease in rheumatoid arthritis. Biomed Pharmacother, 2006, 60, 10, 673–677. [CrossRef] [PubMed] [Google Scholar]
  • Gupta R.A., Tan J., Krause W.F., Geraci M.W., Willson T.M., Dey S.K. & DuBois R.N., Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci U S A, 2000, 97, 24, 13275–13280. [CrossRef] [PubMed] [Google Scholar]
  • Hashimoto S., Takahashi K., Amiel D., Coutts R.D. & Lotz M., Chondrocyte apoptosis and nitric oxide production during experimentally induced osteoarthritis. Arthritis Rheum, 1998, 41, 7, 1266–1274. [CrossRef] [PubMed] [Google Scholar]
  • Hauselmann H.J., Aydelotte M.B., Schumacher B.L., Kuettner K.E., Gitelis S.H. & Thonar E.J., Synthesis and turnover of proteoglycans by human and bovine adult articular chondrocytes cultured in alginate beads. Matrix, 1992, 12, 2, 116–129. [CrossRef] [PubMed] [Google Scholar]
  • He T.C., Chan T.A., Vogelstein B. & Kinzler K.W., PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell, 1999, 99, 3, 335–345. [CrossRef] [PubMed] [Google Scholar]
  • Heikkinen S., Auwerx J. & Argmann C.A., PPARgamma in human and mouse physiology. Biochim Biophys Acta, 2007, 1771, 8, 999–1013. [CrossRef] [PubMed] [Google Scholar]
  • Heinaniemi M., Uski J.O., Degenhardt T. & Carlberg C., Meta-analysis of primary target genes of peroxisome proliferator-activated receptors. Genome Biol, 2007, 8, 7, R147. [CrossRef] [PubMed] [Google Scholar]
  • Henke B.R., Blanchard S.G., Brackeen M.F., Brown K.K., Cobb J.E., Collins J.L., Harrington W.W., Jr., Hashim M.A., Hull-Ryde E.A., Kaldor I., Kliewer S.A., Lake D.H., Leesnitzer L.M., Lehmann J.M., Lenhard J.M., Orband-Miller L.A., Miller J.F., Mook R.A., Jr., Noble S.A., Oliver W., Jr., Parks D.J., Plunket K.D., Szewczyk J.R. & Willson T.M., N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J Med Chem, 1998, 41, 25, 5020–5036. [CrossRef] [PubMed] [Google Scholar]
  • Huang J.T., Welch J.S., Ricote M., Binder C.J., Willson T.M., Kelly C., Witztum J.L., C.D. Funk, Conrad D. & Glass C.K., Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature, 1999, 400, 6742, 378–382. [CrossRef] [PubMed] [Google Scholar]
  • IJpenberg A., Tan N.S., Gelman L., Kersten S., Seydoux J., Xu J., Metzger D., Canaple L., Chambon P., Wahli W. & Desvergne B., In vivo activation of PPAR target genes by RXR homodimers. EMBO J, 2004, 23, 10, 2083–2091. [CrossRef] [PubMed] [Google Scholar]
  • Imai K., Ohta S., Matsumoto T., Fujimoto N., Sato H., Seiki M. & Okada Y., Expression of membrane-type 1 matrix metalloproteinase and activation of progelatinase A in human osteoarthritic cartilage. Am J Pathol, 1997, 151, 1, 245–256. [PubMed] [Google Scholar]
  • Inoue H., Takamori M., Shimoyama Y., Ishibashi H., Yamamoto S. & Koshihara Y., Regulation by PGE2 of the production of interleukin-6, macrophage colony stimulating factor, and vascular endothelial growth factor in human synovial fibroblasts. Br J Pharmacol, 2002, 136, 2, 287–295. [CrossRef] [PubMed] [Google Scholar]
  • Jackson S.M. & Demer L.L., Peroxisome proliferator-activated receptor activators modulate the osteoblastic maturation of MC3T3-E1 preosteoblasts. FEBS Lett, 2000, 471, 1, 119–124. [CrossRef] [PubMed] [Google Scholar]
  • Jang D. & Murrell G.A., Nitric oxide in arthritis. Free Radic Biol Med, 1998, 24, 9, 1511–1519. [CrossRef] [PubMed] [Google Scholar]
  • Janusz M.J., Hookfin E.B., Heitmeyer S.A., Woessner J.F., Freemont A.J., Hoyland J.A., Brown K.K., Hsieh L.C., Almstead N.G., De B., Natchus M.G., Pikul S. & Taiwo Y.O., Moderation of iodoacetate-induced experimental osteoarthritis in rats by matrix metalloproteinase inhibitors. Osteoarthritis Cartilage, 2001, 9, 8, 751–760. [CrossRef] [PubMed] [Google Scholar]
  • Ji J.D., Cheon H., Jun J.B., Choi S.J., Kim Y.R., Lee Y.H., Kim T.H., Chae I.J., Song G.G., Yoo D.H., Kim S.Y. & Sohn J., Effects of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) on the expression of inflammatory cytokines and apoptosis induction in rheumatoid synovial fibroblasts and monocytes. J Autoimmun, 2001, 17, 3, 215–221. [CrossRef] [PubMed] [Google Scholar]
  • Jiang C., Ting A.T. & Seed B., PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature, 1998, 391, 6662, 82–86. [CrossRef] [PubMed] [Google Scholar]
  • Jimi E., Aoki K., Saito H., D'Acquisto F., May M.J., Nakamura I., Sudo T., Kojima T., Okamoto F., Fukushima H., Okabe K., Ohya K. & Ghosh S., Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med, 2004, 10, 6, 617–624. [CrossRef] [PubMed] [Google Scholar]
  • Jones G.C. & Riley G.P., ADAMTS proteinases: a multi-domain, multi-functional family with roles in extracellular matrix turnover and arthritis. Arthritis Res Ther, 2005, 7, 4, 160–169. [CrossRef] [PubMed] [Google Scholar]
  • Jouzeau J.Y., Terlain B., Abid A., Nedelec E. & Netter P., Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs. Drugs, 1997, 53, 4, 563–582. [CrossRef] [PubMed] [Google Scholar]
  • Kalajdzic T., Faour W.H., He Q.W., Fahmi H., Martel-Pelletier J., Pelletier J.P. & Di Battista J.A., Nimesulide, a preferential cyclooxygenase 2 inhibitor, suppresses peroxisome proliferator-activated receptor induction of cyclooxygenase 2 gene expression in human synovial fibroblasts: evidence for receptor antagonism. Arthritis Rheum, 2002, 46, 2, 494–506. [CrossRef] [PubMed] [Google Scholar]
  • Kannan K., Ortmann R.A. & Kimpel D., Animal models of rheumatoid arthritis and their relevance to human disease. Pathophysiology, 2005, 12, 3, 167–181. [CrossRef] [PubMed] [Google Scholar]
  • Kawahito Y., Kondo M., Tsubouchi Y., Hashiramoto A., Bishop-Bailey D., Inoue K., Kohno M., Yamada R., Hla T. & Sano H., 15-deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest, 2000, 106, 2, 189–197. [CrossRef] [PubMed] [Google Scholar]
  • Kersten S., Desvergne & Wahli W., Roles of PPARs in health and disease. Nature, 2000, 405, 6785, 421–424. [CrossRef] [PubMed] [Google Scholar]
  • Kim H.A. & F.J. Blanco, Cell death and apoptosis in osteoarthritic cartilage. Curr Drug Targets, 2007, 8, 2, 333–345. [CrossRef] [PubMed] [Google Scholar]
  • Kliewer S.A., Lenhard J.M., Willson T.M., Patel I., Morris D.C. & Lehmann J.M., A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell, 1995, 83, 5, 813–819. [CrossRef] [PubMed] [Google Scholar]
  • Kliewer S.A., Umesono K., Mangelsdorf D.J. & Evans R.M., Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature, 1992, 355, 6359, 446–449. [CrossRef] [PubMed] [Google Scholar]
  • Klotz L., Dani I., Edenhofer F., Nolden L., Evert B., Paul B., Kolanus W., Klockgether T., Knolle P. & Diehl L., Peroxisome proliferator-activated receptor gamma control of dendritic cell function contributes to development of CD4+ T cell anergy. J Immunol, 2007, 178, 4, 2122–2131. [PubMed] [Google Scholar]
  • Kobayashi T., Notoya K., Naito T., Unno S., Nakamura A., Martel-Pelletier J. & Pelletier J.P., Pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, reduces the progression of experimental osteoarthritis in guinea pigs. Arthritis Rheum, 2005, 52, 2, 479–487. [CrossRef] [PubMed] [Google Scholar]
  • Kobayashi Y., Mizoguchi T., Take I., Kurihara S., Udagawa N. & Takahashi N., Prostaglandin E2 enhances osteoclastic differentiation of precursor cells through protein kinase A-dependent phosphorylation of TAK1. J Biol Chem, 2005, 280, 12, 11395–11403. [CrossRef] [PubMed] [Google Scholar]
  • Kojima F., Naraba H., Miyamoto S., Beppu M., Aoki H. & Kawai S., Membrane-associated prostaglandin E synthase-1 is upregulated by proinflammatory cytokines in chondrocytes from patients with osteoarthritis. Arthritis Res Ther, 2004, 6, 4, R355–65. [CrossRef] [PubMed] [Google Scholar]
  • Koufany M., Moulin D., Bianchi A., Muresan M., Sebillaud S., Netter P., Weryha G. & Jouzeau J.Y., Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis. Arthritis Res Ther, 2008, 10, 1, R6. [CrossRef] [PubMed] [Google Scholar]
  • Krey G., Braissant O., L'Horset F., Kalkhoven E., Perroud M., Parker M.G. & Wahli W., Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol, 1997, 11, 6, 779–791. [CrossRef] [PubMed] [Google Scholar]
  • Landino L.M., Crews B.C., Timmons M.D., Morrow J.D. & Marnett L.J., Peroxynitrite, the coupling product of nitric oxide and superoxide, activates prostaglandin biosynthesis. Proc Natl Acad Sci U S A, 1996, 93, 26, 15069–15074. [CrossRef] [PubMed] [Google Scholar]
  • Lecka-Czernik B., Moerman E.J., Grant D.F., Lehmann J.M., Manolagas S.C. & Jilka R.L., Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology, 2002, 143, 6, 2376–2384. [CrossRef] [PubMed] [Google Scholar]
  • Lehmann J.M., Lenhard J.M., Oliver B.B., Ringold G.M. & Kliewer S.A., Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem, 1997, 272, 6, 3406–3410. [CrossRef] [PubMed] [Google Scholar]
  • Li T.F., O'Keefe R.J. & Chen D., TGF-beta signaling in chondrocytes. Front Biosci, 2005, 10, 681–688. [CrossRef] [PubMed] [Google Scholar]
  • Li, X., Afif H., Cheng S., Martel-Pelletier J., Pelletier J.P., Ranger P. & Fahmi H., Expression and regulation of microsomal prostaglandin E synthase-1 in human osteoarthritic cartilage and chondrocytes. J Rheumatol, 2005, 32, 5, 887–895. [PubMed] [Google Scholar]
  • Lin M.S., Chen W.C., Bai X. & Wang Y.D., Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer. J Dig Dis, 2007, 8, 2, 82–88. [CrossRef] [PubMed] [Google Scholar]
  • Lowe G.N., Fu Y.H., McDougall S., Polendo R., Williams A., Benya P.D. & Hahn T.J., Effects of prostaglandins on deoxyribonucleic acid and aggrecan synthesis in the RCJ 3.1C5.18 chondrocyte cell line: role of second messengers. Endocrinology, 1996, 137, 6, 2208–2216. [CrossRef] [PubMed] [Google Scholar]
  • Martel-Pelletier J., Pelletier J.P. & Fahmi H., Cyclooxygenase-2 and prostaglandins in articular tissues. Semin Arthritis Rheum, 2003, 33, 3, 155–167. [CrossRef] [PubMed] [Google Scholar]
  • Marx N., Kehrle B., Kohlhammer K., Grub M., Koenig W., Hombach V., Libby P. & Plutzky J., PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res, 2002, 90, 6, 703–710. [CrossRef] [PubMed] [Google Scholar]
  • Marx N., Schonbeck U., Lazar M.A., Libby P. & Plutzky J., Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res, 1998, 83, 11, 1097–1103. [CrossRef] [PubMed] [Google Scholar]
  • Masuko-Hongo K., Berenbaum F., Humbert L., Salvat C., Goldring M.B. & Thirion S., Up-regulation of microsomal prostaglandin E synthase 1 in osteoarthritic human cartilage: critical roles of the ERK-1/2 and p38 signaling pathways. Arthritis Rheum, 2004, 50, 9, 2829–2838. [CrossRef] [PubMed] [Google Scholar]
  • Maurin A.C., Chavassieux P.M. & Meunier P.J., Expression of PPARgamma and beta/delta in human primary osteoblastic cells: influence of polyunsaturated fatty acids. Calcif Tissue Int, 2005, 76, 5, 385–392. [CrossRef] [PubMed] [Google Scholar]
  • Mbalaviele G., Abu-Amer Y., Meng A., Jaiswal R., Beck S., Pittenger M.F., Thiede M.A. & Marshak D.R., Activation of peroxisome proliferator-activated receptor-gamma pathway inhibits osteoclast differentiation. J Biol Chem, 2000, 275, 19, 14388–14393. [CrossRef] [PubMed] [Google Scholar]
  • Meade E.A., McIntyre T.M., Zimmerman G.A. & Prescott S.M., Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells. J Biol Chem, 1999, 274, 12, 8328–8334. [CrossRef] [PubMed] [Google Scholar]
  • Meier C.A., Chicheportiche R., Juge-Aubry C.E., Dreyer M.G. & Dayer J.M., Regulation of the interleukin-1 receptor antagonist in THP-1 cells by ligands of the peroxisome proliferator-activated receptor gamma. Cytokine, 2002, 18, 6, 320–328. [CrossRef] [PubMed] [Google Scholar]
  • Merx H., Dreinhofer K., Schrader P., Sturmer T., Puhl W., Gunther K.P. & Brenner H., International variation in hip replacement rates. Ann Rheum Dis, 2003, 62, 3, 222–226. [CrossRef] [PubMed] [Google Scholar]
  • Michalik L. & Wahli W., Involvement of PPAR nuclear receptors in tissue injury and wound repair. J Clin Invest, 2006, 116, 3, 598–606. [CrossRef] [PubMed] [Google Scholar]
  • Moulin D., Bianchi A., Boyault S., Sebillaud S., Koufany M., François M., Netter P., Jouzeau J.Y. & Terlain B., Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism. Arthritis Rheum, 2005, 52, 3, 759–769. [CrossRef] [PubMed] [Google Scholar]
  • Nagase H. & Kashiwagi M., Aggrecanases and cartilage matrix degradation. Arthritis Res Ther, 2003, 5, 2, 94–103. [CrossRef] [PubMed] [Google Scholar]
  • Nagy L., Tontonoz P., Alvarez J.G., Chen H. & Evans R.M., Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell, 1998, 93, 2, 229–240. [CrossRef] [PubMed] [Google Scholar]
  • Nicola P.J., Maradit-Kremers H., Roger V.L., Jacobsen S.J., Crowson C.S., Ballman K.V. & Gabriel S.E., The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum, 2005, 52, 2, 412–420. [CrossRef] [PubMed] [Google Scholar]
  • NIH consensus panel, NIH Consensus Statement on total knee replacement December 8-10, 2003. J Bone Joint Surg Am, 2004, 86–A, 6, 1328–1335. [Google Scholar]
  • Nixon R., Bansback N. & Brennan A., The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. Rheumatology (Oxford), 2007, 46, 7, 1140–1147. [CrossRef] [PubMed] [Google Scholar]
  • Okamoto H., Iwamoto T., Kotake S., Momohara S., Yamanaka H. & Kamatani N., Inhibition of NF-kappaB signaling by fenofibrate, a peroxisome proliferator-activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis. Clin Exp Rheumatol, 2005, 23, 3, 323–330. [PubMed] [Google Scholar]
  • Okamoto H. & Kamatani N., Successful treatment with fenofibrate, a peroxisome proliferator activated receptor alpha ligand, for a patient with rheumatoid arthritis. Ann Rheum Dis, 2004, 63, 8, 1002–1003. [CrossRef] [PubMed] [Google Scholar]
  • Oliver W.R., Jr., Shenk J.L., Snaith M.R., Russell C.S., Plunket K.D., Bodkin N.L., Lewis M.C., Winegar D.A., Sznaidman M.L., Lambert M.H., Xu H.E., Sternbach D.D., Kliewer S.A., Hansen B.C. & Willson T.M., A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci U S A, 2001, 98, 9, 5306–5311. [CrossRef] [PubMed] [Google Scholar]
  • Pacquelet S., Presle N., Boileau C., Dumond H., Netter P., Martel-Pelletier J., Pelletier J.P., Terlain B. & Jouzeau J.Y., Interleukin 17, a nitric oxide-producing cytokine with a peroxynitrite-independent inhibitory effect on proteoglycan synthesis. J Rheumatol, 2002, 29, 12, 2602–2610. [PubMed] [Google Scholar]
  • Palmer R.M., Hickery M.S., Charles I.G., Moncada S. & Bayliss M.T., Induction of nitric oxide synthase in human chondrocytes. Biochem Biophys Res Commun, 1993, 193, 1, 398–405. [CrossRef] [PubMed] [Google Scholar]
  • Pelletier J.P., Caron J.P., Evans C., Robbins P.D., Georgescu H.I., Jovanovic D., Fernandes J.C. & Martel-Pelletier J., In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum, 1997, 40, 6, 1012–1019. [CrossRef] [PubMed] [Google Scholar]
  • Pelletier J.P., Fernandes J.C., Jovanovic D.V., Reboul P. & Martel-Pelletier J., Chondrocyte death in experimental osteoarthritis is mediated by MEK 1/2 and p38 pathways: role of cyclooxygenase-2 and inducible nitric oxide synthase. J Rheumatol, 2001, 28, 11, 2509–2519. [PubMed] [Google Scholar]
  • Pelletier, J.P., Jovanovic D., Fernandes J.C., Manning P., Connor J.R., Currie M.G., Di Battista J.A. & Martel-Pelletier J., Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase. Arthritis Rheum, 1998, 41, 7, 1275–1286. [CrossRef] [MathSciNet] [PubMed] [Google Scholar]
  • Pelletier J.P., Martel-Pelletier J. & Abramson S.B., Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Arthritis Rheum, 2001, 44, 6, 1237–1247. [CrossRef] [PubMed] [Google Scholar]
  • Perez-Sala D., Cernuda-Morollon E. & Canada F.J., Molecular basis for the direct inhibition of AP-1 DNA binding by 15-deoxy-Delta 12,14-prostaglandin J2. J Biol Chem, 2003, 278, 51, 51251–51260. [CrossRef] [PubMed] [Google Scholar]
  • Poleni P.E., Bianchi A., Etienne S., Koufany M., Sebillaud S., Netter P., Terlain B. & Jouzeau J.Y., Agonists of peroxisome proliferators-activated receptors (PPAR) alpha, beta/delta or gamma reduce transforming growth factor (TGF)-beta-induced proteoglycans' production in chondrocytes. Osteoarthritis Cartilage, 2006. [Google Scholar]
  • Porter S., Clark I.M., Kevorkian L. & Edwards D.R., The ADAMTS metalloproteinases. Biochem J, 2005, 386, Pt 1, 15–27. [Google Scholar]
  • Poynter M.E. & Daynes R.A., Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem, 1998, 273, 49, 32833–32841. [CrossRef] [PubMed] [Google Scholar]
  • Presle N., Pottie P., Dumond H., Guillaume C., Lapicque F., Pallu S., Mainard D., Netter P. & Terlain B., Differential distribution of adipokines between serum and synovial fluid in patients with osteoarthritis. Contribution of joint tissues to their articular production. Osteoarthritis Cartilage, 2006, 14, 7, 690–695. [CrossRef] [PubMed] [Google Scholar]
  • Rannou F., François M., Corvol M.T. & Berenbaum F., Cartilage breakdown in rheumatoid arthritis. Joint Bone Spine, 2006, 73, 1, 29–36. [CrossRef] [PubMed] [Google Scholar]
  • Reboul P., Pelletier J.P., Tardif G., Cloutier J.M. & Martel-Pelletier J., The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes. A role in osteoarthritis. J Clin Invest, 1996, 97, 9, 2011–2019. [CrossRef] [PubMed] [Google Scholar]
  • Relic B., Benoit V., Franchimont N., Ribbens C., Kaiser M.J., Gillet P., Merville M.P., Bours V. & Malaise M.G., 15-deoxy-delta12,14-prostaglandin J2 inhibits Bay 11-7085-induced sustained extracellular signal-regulated kinase phosphorylation and apoptosis in human articular chondrocytes and synovial fibroblasts. J Biol Chem, 2004, 279, 21, 22399–22403. [CrossRef] [PubMed] [Google Scholar]
  • Ricote M., Li A.C., Willson T.M., Kelly C.J. & Glass C.K., The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature, 1998, 391, 6662, 79–82. [CrossRef] [PubMed] [Google Scholar]
  • Rossi A., Kapahi P., Natoli G., Takahashi T., Chen Y., Karin M. & Santoro M.G., Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature, 2000, 403, 6765, 103–108. [CrossRef] [PubMed] [Google Scholar]
  • Rubenstrunk A., Hanf R., Hum D.W., Fruchart J.C. & Staels B., Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta, 2007, 1771, 8, 1065–1081. [CrossRef] [PubMed] [Google Scholar]
  • Sabatini M., Bardiot A., Lesur C., Moulharat N., Thomas M., Richard I. & Fradin A., Effects of agonists of peroxisome proliferator-activated receptor gamma on proteoglycan degradation and matrix metalloproteinase production in rat cartilage in vitro. Osteoarthritis Cartilage, 2002, 10, 9, 673–679. [CrossRef] [PubMed] [Google Scholar]
  • Sadowski T. & Steinmeyer J., Effects of non-steroidal antiinflammatory drugs and dexamethasone on the activity and expression of matrix metalloproteinase-1, matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 by bovine articular chondrocytes. Osteoarthritis Cartilage, 2001, 9, 5, 407–415. [CrossRef] [PubMed] [Google Scholar]
  • Sakurai A. & Hashizume K., Deterioration of rheumatoid arthritis with troglitazone: a rare and unexpected adverse effect. Arch Intern Med, 2000, 160, 1, 118–119. [CrossRef] [Google Scholar]
  • Scher J.U., Pillinger M.H. & Abramson S.B., Nitric oxide synthases and osteoarthritis. Curr Rheumatol Rep, 2007, 9, 1, 9–15. [CrossRef] [PubMed] [Google Scholar]
  • Schoonjans K., Staels B. & Abramson S.B., Nitric oxide synthases and J. Auwerx, The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta, 1996, 1302, 2, 93–109. [Google Scholar]
  • Scott D.L. & Kingsley G.H., Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med, 2006, 355, 7, 704–712. [CrossRef] [PubMed] [Google Scholar]
  • Seimandi M., Lemaire G., Pillon A., Perrin A., Carlavan I., Voegel J.J., Vignon F., Nicolas J.C. & Balaguer P., Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands. Anal Biochem, 2005, 344, 1, 8–15. [CrossRef] [PubMed] [Google Scholar]
  • Shan Z.Z., Masuko-Hongo K., Dai S.M., Nakamura H., Kato T. & Nishioka K., A potential role of 15-deoxy-delta(12,14)-prostaglandin J2 for induction of human articular chondrocyte apoptosis in arthritis. J Biol Chem, 2004, 279, 36, 37939–37950. [CrossRef] [PubMed] [Google Scholar]
  • Shao Y.Y., Wang L., Hicks D.G., Tarr S. & Ballock R.T., Expression and activation of peroxisome proliferator-activated receptors in growth plate chondrocytes. J Orthop Res, 2005, 23, 5, 1139–1145. [CrossRef] [PubMed] [Google Scholar]
  • Shaw T., Nixon J.S. & Bottomley K.M., Metalloproteinase inhibitors: new opportunities for the treatment of rheumatoid arthritis and osteoarthritis. Expert Opin Investig Drugs, 2000, 9, 7, 1469–1478. [CrossRef] [PubMed] [Google Scholar]
  • Shiojiri T., Wada K., Nakajima A., Katayama K., Shibuya A., Kudo C., Kadowaki T., Mayumi T., Yura Y. & Kamisaki Y., PPAR gamma ligands inhibit nitrotyrosine formation and inflammatory mediator expressions in adjuvant-induced rheumatoid arthritis mice. Eur J Pharmacol, 2002, 448, 2–3, 231–238. [CrossRef] [PubMed] [Google Scholar]
  • Shipley J.M. & Waxman D.J., Down-regulation of STAT5b transcriptional activity by ligand-activated peroxisome proliferator-activated receptor (PPAR) alpha and PPARgamma. Mol Pharmacol, 2003, 64, 2, 355–364. [CrossRef] [PubMed] [Google Scholar]
  • Simonin M.A., Bordji K., Boyault S., Bianchi A., Gouze E., Becuwe P., Dauca M., Netter P. & Terlain B., PPAR-gamma ligands modulate effects of LPS in stimulated rat synovial fibroblasts. Am J Physiol Cell Physiol, 2002, 282, 1, C125–133. [PubMed] [Google Scholar]
  • Smeets T.J., Barg E.C., Kraan M.C., Smith M.D., Breedveld F.C. & Tak P.P., Analysis of the cell infiltrate and expression of proinflammatory cytokines and matrix metalloproteinases in arthroscopic synovial biopsies: comparison with synovial samples from patients with end stage, destructive rheumatoid arthritis. Ann Rheum Dis, 2003, 62, 7, 635–638. [CrossRef] [PubMed] [Google Scholar]
  • Smolen J.S., Aletaha D., Koeller M., Weisman M.H. & Emery P., New therapies for treatment of rheumatoid arthritis. Lancet, 2007, 370, 9602, 1861–1874. [CrossRef] [PubMed] [Google Scholar]
  • Sporn M.B. & Roberts A.B., Transforming growth factor-beta. Multiple actions and potential clinical applications. Jama, 1989, 262, 7, 938–941. [CrossRef] [PubMed] [Google Scholar]
  • Stadler J., Stefanovic-Racic M., Billiar T.R., Curran R.D., McIntyre L.A., Georgescu H.I., Simmons R.L. & Evans C.H., Articular chondrocytes synthesize nitric oxide in response to cytokines and lipopolysaccharide. J Immunol, 1991, 147, 11, 3915–3920. [PubMed] [Google Scholar]
  • Staels B., Koenig W., Habib A., Merval R., Lebret M., Torra I.P., Delerive P., Fadel A., Chinetti G., Fruchart J.C., Najib J., Maclouf J. & Tedgui A., Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature, 1998, 393, 6687, 790–793. [CrossRef] [PubMed] [Google Scholar]
  • Stefanovic-Racic M., Meyers K., Meschter C., Coffey J.W., Hoffman R.A. & Evans C.H., N-monomethyl arginine, an inhibitor of nitric oxide synthase, suppresses the development of adjuvant arthritis in rats. Arthritis Rheum, 1994, 37, 7, 1062–1069. [CrossRef] [PubMed] [Google Scholar]
  • Stichtenoth D.O., Thoren S., Bian H., Peters-Golden M., Jakobsson P.J. & Crofford L.J., Microsomal prostaglandin E synthase is regulated by proinflammatory cytokines and glucocorticoids in primary rheumatoid synovial cells. J Immunol, 2001, 167, 1, 469–474. [PubMed] [Google Scholar]
  • Straus D.S., Pascual G., Li M., Welch J.S., Ricote M., Hsiang C.H., Sengchanthalangsy L.L., Ghosh G. & Glass C.K., 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc Natl Acad Sci U S A, 2000, 97, 9, 4844–4849. [CrossRef] [PubMed] [Google Scholar]
  • Sturmer T., Brenner H., Brenner R.E. & Gunther K.P., Non-insulin dependent diabetes mellitus (NIDDM) and patterns of osteoarthritis. The Ulm osteoarthritis study. Scand J Rheumatol, 2001, 30, 3, 169–171. [CrossRef] [PubMed] [Google Scholar]
  • Szatmari I., Rajnavolgyi E. & Nagy L., PPARgamma, a lipid-activated transcription factor as a regulator of dendritic cell function. Ann N Y Acad Sci, 2006, 1088, 207–218. [CrossRef] [PubMed] [Google Scholar]
  • Szeles L., Torocsik D. & Nagy L., PPARgamma in immunity and inflammation: cell types and diseases. Biochim Biophys Acta, 2007, 1771, 8, 1014–1030. [CrossRef] [PubMed] [Google Scholar]
  • Tanaka T., Yamamoto J., Iwasaki S., Asaba H., Hamura H., Ikeda Y., Watanabe M., Magoori K., Ioka R.X., Tachibana K., Watanabe Y., Uchiyama Y., Sumi K., Iguchi H., Ito S., Doi T., Hamakubo T., Naito M., Auwerx J., Yanagisawa M., Kodama T. & Sakai J., Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci U S A, 2003, 100, 26, 15924–15929. [CrossRef] [PubMed] [Google Scholar]
  • Thyss R., Virolle V., Imbert V., Peyron J.F., Aberdam D. & Virolle T., NF-kappaB/Egr-1/Gadd45 are sequentially activated upon UVB irradiation to mediate epidermal cell death. Embo J, 2005, 24, 1, 128–137. [CrossRef] [PubMed] [Google Scholar]
  • Tomita T., Kakiuchi Y. & Tsao P.S., THR0921, a novel peroxisome proliferator-activated receptor gamma agonist, reduces the severity of collagen-induced arthritis. Arthritis Res Ther, 2006, 8, 1, R7. [CrossRef] [PubMed] [Google Scholar]
  • Tsubouchi Y., Kawahito Y., Kohno M., Inoue K., Hla T. & Sano H., Feedback control of the arachidonate cascade in rheumatoid synoviocytes by 15-deoxy-Delta(12,14)-prostaglandin J2. Biochem Biophys Res Commun, 2001, 283, 4, 750–755. [CrossRef] [PubMed] [Google Scholar]
  • Tsuchida A., Yamauchi T. & Kadowaki T., Nuclear receptors as targets for drug development: molecular mechanisms for regulation of obesity and insulin resistance by peroxisome proliferator-activated receptor gamma, CREB-binding protein, and adiponectin. J Pharmacol Sci, 2005, 97, 2, 164–170. [CrossRef] [PubMed] [Google Scholar]
  • Ushiyama T., Chano T., Inoue K. & Matsusue Y., Cytokine production in the infrapatellar fat pad: another source of cytokines in knee synovial fluids. Ann Rheum Dis, 2003, 62, 2, 108–112. [CrossRef] [PubMed] [Google Scholar]
  • van Beuningen H.M., Glansbeek H.L., van der Kraan P.M. & van den Berg W.B., Differential effects of local application of BMP-2 or TGF-beta 1 on both articular cartilage composition and osteophyte formation. Osteoarthritis Cartilage, 1998, 6, 5, 306–317. [CrossRef] [PubMed] [Google Scholar]
  • van Beuningen H.M., van der Kraan P.M., Arntz O.J. & van den Berg W.B., Transforming growth factor-beta 1 stimulates articular chondrocyte proteoglycan synthesis and induces osteophyte formation in the murine knee joint. Lab Invest, 1994, 71, 2, 279–290. [PubMed] [Google Scholar]
  • Van den Berg W.B., Lessons from animal models of arthritis. Curr Rheumatol Rep, 2002, 4, 3, 232–239. [CrossRef] [PubMed] [Google Scholar]
  • van Osch G.J., van den Berg W.B., Hunziker E.B. & Hauselmann H.J., Differential effects of IGF-1 and TGF beta-2 on the assembly of proteoglycans in pericellular and territorial matrix by cultured bovine articular chondrocytes. Osteoarthritis Cartilage, 1998, 6, 3, 187–195. [CrossRef] [PubMed] [Google Scholar]
  • Wahli W., Peroxisome proliferator-activated receptors (PPARs): from metabolic control to epidermal wound healing. Swiss Med Wkly, 2002, 132, 7–8, 83–91. [PubMed] [Google Scholar]
  • Wang Y.X., Zhang C.L., Yu R.T., Cho H.K., Nelson M.C., Bayuga-Ocampo C.R., Ham J., Kang H. & Evans R.M., Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol, 2004, 2, 10, e294. [Google Scholar]
  • Who Scientific Group, The burden of musculoskeletal conditions at the start of the new millennium. World Health Organ Tech Rep Ser, 2003, 919, i–x, 1–218. [Google Scholar]
  • Wieland H.A., Michaelis M., Kirschbaum B.J. & Rudolphi K.A., Osteoarthritis - an untreatable disease? Nat Rev Drug Discov, 2005, 4, 4, 331–344. [Google Scholar]
  • Wiesenberg I., Chiesi M., Missbach M., Spanka C., Pignat W. & Carlberg C., Specific activation of the nuclear receptors PPARgamma and RORA by the antidiabetic thiazolidinedione BRL 49653 and the antiarthritic thiazolidinedione derivative CGP 52608. Mol Pharmacol, 1998, 53, 6, 1131–1138. [PubMed] [Google Scholar]
  • Williams R.O., Mauri C., Mason L.J., Marinova-Mutafchieva L., Ross S.E., Feldmann M. & Maini R.N., Therapeutic actions of cyclosporine and anti-tumor necrosis factor alpha in collagen-induced arthritis and the effect of combination therapy. Arthritis Rheum, 1998, 41, 10, 1806–1812. [CrossRef] [PubMed] [Google Scholar]
  • Willson T.M., Brown P.J., Sternbach D.D. & Henke B.R., The PPARs: from orphan receptors to drug discovery. J Med Chem, 2000, 43, 4, 527–550. [CrossRef] [PubMed] [Google Scholar]
  • Willson T.M., Lehmann J.M. & Kliewer S.A., Discovery of ligands for the nuclear peroxisome proliferator-activated receptors. Ann N Y Acad Sci, 1996, 804, 276–283. [CrossRef] [PubMed] [Google Scholar]
  • Yamasaki S., Nakashima T., Kawakami A., Miyashita T., Ida H., Migita K., Nakata K. & Eguchi K., Functional changes in rheumatoid fibroblast-like synovial cells through activation of peroxisome proliferator-activated receptor gamma-mediated signalling pathway. Clin Exp Immunol, 2002, 129, 2, 379–384. [CrossRef] [PubMed] [Google Scholar]
  • Yamazaki R., Kusunoki N., Matsuzaki T., Hashimoto S. & Kawai S., Nonsteroidal anti-inflammatory drugs induce apoptosis in association with activation of peroxisome proliferator-activated receptor gamma in rheumatoid synovial cells. J Pharmacol Exp Ther, 2002, 302, 1, 18–25. [CrossRef] [PubMed] [Google Scholar]
  • Yoshida K., Oida H., Kobayashi T., Maruyama T., Tanaka M., Katayama T., Yamaguchi K., Segi E., Tsuboyama T., Matsushita M., Ito K., Ito Y., Sugimoto Y., Ushikubi F., Ohuchida S., Kondo K., Nakamura T. & Narumiya S., Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation. Proc Natl Acad Sci U S A, 2002, 99, 7, 4580–4585. [CrossRef] [PubMed] [Google Scholar]
  • Zhang W., Moskowitz R.W., Nuki G., Abramson S., Altman R.D., Arden N., Bierma-Zeinstra S., Brandt K.D., Croft P., Doherty M., Dougados M., Hochberg M., Hunter D.J., Kwoh K., Lohmander L.S. & Tugwell P., OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage, 2008, 16, 2, 137–162. [CrossRef] [PubMed] [Google Scholar]
  • Zheng F., Fornoni A., Elliot S.J., Guan Y., Breyer M.D., Striker L.J. & Striker G.E., Upregulation of type I collagen by TGF-beta in mesangial cells is blocked by PPARgamma activation. Am J Physiol Renal Physiol, 2002, 282, 4, F639–648. [PubMed] [Google Scholar]
  • Zwerina J., Redlich K., Polzer K., Joosten L., Kronke G., Distler J., Hess A., Pundt N., Pap T., Hoffmann O., Gasser J., Scheinecker C., Smolen J.S., van den Berg W. & Schett G., TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci U S A, 2007, 104, 28, 11742–11747. [CrossRef] [PubMed] [Google Scholar]
  • Zwerina J., Redlich K., Schett G. & Smolen J.S., Pathogenesis of rheumatoid arthritis: targeting cytokines. Ann N Y Acad Sci, 2005, 1051, 716–729. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.